Newly uncovered mechanism could drive next-generation cystic fibrosis treatments
A new study from The Hospital for Sick Children (SickKids) reveals the process underlying protein organization on cell ...
McGill University Health Centre4h
Major funding for research project on cystic fibrosis
A new research project focusing on rare genetic mutations that are linked to cystic fibrosis just received $600,000 in ...
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Technology Networks1d
Newly Uncovered Protein Clustering Mechanism Could Drive New Cystic Fibrosis Treatments
Studying how proteins cluster and organize themselves at the cell membrane could pave the way for innovative cystic fibrosis ...
Modulator shows positive impact on pregnancy outcomes in people with cystic fibrosis
A recent retrospective study published in CHEST evaluated the effects of cystic fibrosis transmembrane conductance regulator ...
BioWorld2d
Adenine base editing corrects G542X mutation in CFTR in patient organoid models
Cystic fibrosis (CF) is a life-threatening autosomal recessive disease affecting over 160,000 people worldwide. CF is caused by loss-of-function mutations in the CF transmembrane conductance regulator ...
Business Wire16d
FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy
Porosome Therapeutics, Inc. announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).
PMLive3d
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...
Pharmabiz4d
UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis
UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will be ...
EurekAlert!2d
Newly uncovered mechanism could drive next-gen cystic fibrosis treatments
Cystic fibrosis (CF) is a genetic condition that affects the lungs, pancreas and other organs, caused by variations on the cystic fibrosis transmembrane conductance regulator  (CFTR) gene. There are ...
EurekAlert!5d
Research shows positive impact of CFTR modulators on pregnancy outcomes in people with cystic fibrosis
A recent retrospective study published in CHEST(Opens in a new window) evaluated the effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use on pregnancy outcomes in ...